Phase II Trial of BAY 43-9006 [sorafenib] in Patients With Advanced Anaplastic Carcinoma of the Thyroid.
Phase of Trial: Phase II
Latest Information Update: 15 Dec 2017
At a glance
- Drugs Sorafenib (Primary)
- Indications Thyroid cancer
- Focus Therapeutic Use
- 17 Jan 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 09 Jan 2013 Planned End Date changed from 1 Oct 2012 to 1 Sep 2011 as reported by ClinicalTrials.gov.
- 14 Nov 2012 Status changed from discontinued to active, no longer recruiting as reported by ClinicalTrials.gov.